Dendritic cells (DCs) are essential components of the immune system, serving as a critical link between innate and adaptive immune responses. These specialized immune cells are adept at recognizing, capturing, and processing pathogens, which they encounter in various tissues such as lymphoid organs, skin, and mucosal surfaces. Once they process antigens, dendritic cells present them on their cell surface to T cells, initiating and shaping the body’s immune responses. The development, activation, and function of dendritic cells are tightly regulated by a network of transcription factors, cytokines, and cell surface receptors, ensuring precise control over immune system activity and the maintenance of immune homeostasis. By orchestrating the activation of T cells and other immune responses, dendritic cells DCs play a pivotal role in defending the body against infections and maintaining overall immune health.

Dendritic Cell Subsets

Dendritic cells are a diverse group, with several distinct subsets that each play unique roles in the immune system. Among these, classical dendritic cells (cDCs) are divided into cDC1 and cDC2 subsets. cDC1 cells are particularly skilled at cross-presenting antigens to CD8+ T cells, which is crucial for initiating responses against intracellular pathogens and tumors. In contrast, cDC2 cells specialize in presenting antigens to CD4+ T cells, supporting a broad range of immune responses. Plasmacytoid dendritic cells (pDCs) represent another important subset, known for their rapid and robust production of type I interferons during viral infections. The ability of different DC subsets, including plasmacytoid dendritic cells PDCs, to respond to various pathogens and activate specific T cell populations is fundamental to effective immune surveillance and the development of targeted immune therapies.

Dendritic Cell Development

The development of dendritic cells begins in the bone marrow, where hematopoietic stem cells give rise to common DC progenitors. This process is orchestrated by a suite of transcription factors, such as IRF8, BATF3, and PU.1, which guide the differentiation of these progenitors into distinct dendritic cell lineages. As dendritic cell precursors mature, they migrate from the bone marrow to peripheral tissues, where they undergo further maturation influenced by local cytokines, chemokines, and cell surface interactions. The dynamic regulation of dendritic cell development ensures that the immune system maintains a pool of functional DCs ready to respond to pathogens and other immune challenges. Understanding the molecular mechanisms that govern dendritic cell development is key to manipulating DC function for therapeutic purposes.

Conventional or myeloid dendritic cells (mDCs) play a central role in shaping adaptive immunity. Originating in the bone marrow, they migrate to peripheral tissues where they act as antigen-presenting cells, bridging innate and adaptive responses. In humans, mDCs are broadly categorized into two subpopulations: CD1c/BDCA-1+ cells, which represent approximately half of the peripheral dendritic cell pool, and CD141/BDCA-3+ cells, which comprise around 5–10%. These subsets differ in their functional properties and tissue distribution, contributing to diverse immunological outcomes. Identification of mDCs typically involves markers such as CD11c and HLA-DR, which help distinguish them from other immune cells. Their presence and activity are frequently studied in immunological research, vaccine development, and disease monitoring. As interest grows in dendritic cell-based therapies and diagnostics, understanding the phenotypic markers and biological roles of mDCs remains a key area of investigation in immunology and translational medicine.

CD11c

CD11c is widely recognized as a dendritic cell marker, particularly for identifying conventional or myeloid dendritic cells in human and murine systems. As an integrin alpha X chain, CD11c contributes to cell adhesion and migration, supporting dendritic cell trafficking to lymphoid tissues. Its expression is commonly assessed through flow cytometry, often in combination with HLA-DR and other lineage markers to distinguish dendritic cells from monocytes and macrophages. While CD11c is not exclusive to dendritic cells, its consistent presence on these cells makes it a reliable indicator in immunophenotyping protocols. Researchers frequently use CD11c to study dendritic cell subsets, monitor immune responses, and explore antigen presentation pathways. In the context of Langerhans cells and other specialized dendritic populations, CD1a is also employed to refine identification, particularly in skin and mucosal tissues. Together, CD11c and CD1a provide valuable insights into dendritic cell biology and their roles in immune surveillance.

Figure 1. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD11c antibody [EP1347Y] - C-terminal (ab52632).

Recommended products

HLA-DR

HLA-DR is a class II major histocompatibility complex (MHC) molecule that plays a central role in antigen presentation by dendritic cells. It is commonly used as a surface marker to identify and characterize dendritic cell subsets in both research and clinical settings. HLA-DR expression reflects the antigen-presenting capacity of dendritic cells and is routinely analyzed by flow cytometry, often in combination with markers such as CD11c, CD1a, and lineage exclusion markers. Its presence helps distinguish dendritic cells from other immune populations, including lymphocytes and granulocytes. HLA-DR is expressed on both myeloid and plasmacytoid dendritic cells, as well as on activated monocytes and B cells, making it a versatile marker in immunophenotyping panels. Researchers studying immune responses, vaccine development, and autoimmune conditions frequently rely on HLA-DR to monitor dendritic cell activation and function across various tissue environments.

Figure 2. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLA-DR antibody [EPR3692] - Low endotoxin, Azide free (ab215985).

Recommended products

Plasmacytoid dendritic cells (pDCs) represent a distinct subset of dendritic cells with specialized functions in antiviral immunity. They originate from both lymphoid organs and the bone marrow, and are characterized by unique surface marker expression that differentiates them from conventional dendritic cells. pDCs are known for their ability to produce large quantities of type I interferons in response to viral infections, contributing to early immune defense and modulation of adaptive responses. Commonly used markers for identifying pDCs include CD123, BDCA-2 (CD303), and BDCA-4 (CD304), which are routinely analyzed by flow cytometry. These markers help distinguish pDCs from other immune cells and support their study in immunological research, disease monitoring, and therapeutic development. The functional properties and tissue distribution of pDCs continue to be explored in contexts such as autoimmunity, cancer, and infectious disease.

CD11c

CD11c is commonly used to identify dendritic cell populations, including subsets of plasmacytoid dendritic cells. In murine bone marrow, pDCs often emerge from CD11c+ MHCII− progenitors, progressing through Siglec-H+ CCR9low stages. While CD11c is not exclusive to pDCs, its expression helps distinguish early developmental stages and supports flow cytometry-based sorting. Researchers studying immune responses, autoimmunity, and antiviral defense frequently rely on CD11c in combination with other markers to track pDC differentiation and function in both steady-state and inflammatory conditions.

Figure 3. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD11c antibody [EP1347Y] - C-terminal (ab52632).

Recommended products

CD123

CD123, the alpha chain of the interleukin-3 receptor, is commonly used to identify plasmacytoid dendritic cells (pDCs) in both research and clinical settings. Its high expression on pDCs allows for reliable detection through flow cytometry and immunohistochemistry. CD123 is also studied in hematologic malignancies like blastic plasmacytoid dendritic cell neoplasm, where it supports diagnostic and therapeutic strategies. While not exclusive to pDCs, CD123 remains a consistent marker for tracking their presence and behavior in immune responses, inflammation, and disease progression.

Figure 4. Flow Cytometry - Anti-IL3RA/CD123 antibody [EPR24481-20] (ab280355).

Recommended products

Langerhans cells (LCs) are a specialized subset of dendritic cells located in the epidermis. They are characterized by the expression of langerin (CD207), a C-type lectin receptor involved in antigen uptake and pathogen recognition. LCs play a key role in skin immune surveillance, forming a dense network that monitors environmental signals. Unlike other dendritic cells, LCs are radioresistant and capable of self-renewal under steady-state conditions. During inflammation, they can be replenished by circulating monocytes. Langerin expression, along with markers like CD1a and E-cadherin, helps distinguish LCs from dermal dendritic cells and other immune populations. These markers are widely used in immunohistochemistry and flow cytometry to study skin immunity, infection, and inflammatory diseases. Understanding LC biology supports research into vaccine delivery, dermatological disorders, and immune tolerance mechanisms in barrier tissues.

CD1a

CD1a is a lipid-presenting molecule highly expressed on Langerhans cells, a dendritic cell subset found in the epidermis. It plays a role in antigen presentation and immune surveillance, particularly in skin-related inflammatory responses. CD1a expression helps distinguish Langerhans cells from other dendritic populations and is widely used in immunohistochemistry and flow cytometry. Researchers studying contact dermatitis, psoriasis and skin immunopathology often rely on CD1a to track immune cell behavior and investigate therapeutic pathways.

Figure 5. Multiplex immunohistochemistry - Anti-CD1a antibody [EPR26526-62] (ab313875).

Recommended products

CD207

CD207, also known as langerin, is a C-type lectin receptor expressed by Langerhans cells in the epidermis. It plays a role in antigen capture and internalization through Birbeck granules, unique organelles found in these cells. CD207 expression helps distinguish Langerhans cells from other dendritic cell subsets in skin and mucosal tissues. Researchers use CD207 in immunophenotyping to study immune responses, skin inflammation, and pathogen interactions, particularly in conditions like contact dermatitis and viral infections.

Figure 6. Multiplex immunohistochemistry - Anti-Langerin antibody [EPR28089-89] (ab317813).

Recommended products

Interdigitating dendritic cells (IDCs) are a specialized subset of antigen-presenting cells primarily located in T cell zones of secondary lymphoid organs. Unlike Langerhans cells or plasmacytoid dendritic cells, IDCs do not express Birbeck granules or langerin. Instead, they are identified by their expression of S100, fascin and HLA-DR, and their lack of lineage-specific markers such as CD1a or CD207. IDCs interact closely with T lymphocytes, facilitating antigen presentation and contributing to immune tolerance and activation. Their morphology is characterized by long cytoplasmic processes that interdigitate with surrounding cells, enhancing cell-to-cell communication. IDCs are often studied in the context of lymphoid tissue architecture, immune surveillance and certain lymphomas. Their marker profile supports their identification in histological and flow cytometric analyses, helping researchers explore their role in immune homeostasis and disease. Understanding IDC biology contributes to broader insights into dendritic cell diversity and function across immune environments.

CD68

CD68 is a glycoprotein commonly used to identify mononuclear phagocytes, including interdigitating dendritic cells (IDCs) in lymphoid tissues. Although traditionally associated with macrophages, CD68 expression in IDCs supports their detection in histological studies. It is mainly localized in the lysosomal compartment but can shuttle to the cell surface. Researchers use CD68 to explore IDC involvement in antigen presentation, immune regulation, and lymphoid architecture, particularly in studies of inflammation, autoimmunity, and lymphoproliferative disorders.

Figure 7. Multiplex immunohistochemistry - Anti-CD68 antibody [SP251] (ab192847).

Recommended products

Follicular dendritic cells (FDCs) are non-hematopoietic stromal cells found in B cell follicles of secondary lymphoid organs. Unlike classical dendritic cells, FDCs do not originate from bone marrow precursors but develop from perivascular stromal cells. They are identified by markers such as CD21, CD35 and CXCL13, which support their role in organizing germinal centers and retaining antigen–antibody complexes. FDCs interact with B cells to promote affinity maturation and memory formation. Their presence is vital for maintaining follicular architecture and facilitating long-term immune responses. Researchers use FDC markers to study lymphoid tissue dynamics, vaccine responses and autoimmune conditions. FDCs are also implicated in certain lymphomas, making their identification relevant in diagnostic pathology. Their unique biology and marker profile distinguish them from other dendritic cell subsets and contribute to a deeper understanding of humoral immunity.

CD1a

CD1a is a lipid-presenting molecule typically associated with Langerhans cells and myeloid dendritic cells. While not a classical marker for follicular dendritic cells (FDCs), CD1a+ cells have been observed in lymphoid infiltrates within certain tumor microenvironments. These cells may contribute to antigen presentation and immune modulation in follicular zones. Researchers studying tumor immunology and lymphoid tissue architecture occasionally include CD1a in marker panels to explore dendritic cell diversity and functional overlap in complex immune landscapes.

Figure 8. Multiplex immunohistochemistry - Anti-CD1a antibody [EPR26526-62] (ab313875).

Recommended products

CD21

CD21, also known as complement receptor 2, is a widely used marker for identifying follicular dendritic cells (FDCs) in secondary lymphoid tissues. It plays a role in capturing immune complexes and presenting antigens to B cells within germinal centers. CD21 expression supports the organization of follicular zones and contributes to long-term antibody responses. Researchers use CD21 in immunohistochemistry and flow cytometry to study FDC function, lymphoid architecture, and immune regulation in health and disease.

Figure 9. Flow Cytometry - Anti-CD21 antibody [EPR27369-9] (ab315160).

Recommended products

CD23

CD23, also known as FcεRII, is a low-affinity IgE receptor expressed on various immune cells, including follicular dendritic cells (FDCs). In lymphoid tissues, CD23 contributes to antigen presentation and regulation of B cell responses. Its interaction with CD21 supports immune complex retention and germinal center formation. Researchers use CD23 expression to study FDC function, immune regulation, and antibody production. CD23 is also investigated in allergy, autoimmunity, and lymphoproliferative disorders for its role in modulating IgE and IgG responses.

Figure 10. Western blot - Anti-CD23 antibody [EPR3617] (ab92495).

Recommended products

CD207

CD207, also known as langerin, is a C-type lectin receptor primarily associated with Langerhans cells. While not a classical marker for follicular dendritic cells (FDCs), CD207 expression has occasionally been observed in dendritic cell neoplasms with overlapping phenotypes. Its presence may reflect transitional or mixed-lineage features in certain immune microenvironments. Researchers investigating dendritic cell diversity and tumor immunology sometimes include CD207 in broader marker panels to explore antigen presentation and cellular plasticity in lymphoid tissues.

Figure 11. Multiplex immunohistochemistry - Anti-Langerin antibody [EPR28089-89] (ab317813).

Recommended products

References

1. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.  Annu. Rev. Immunol.  31, 563–604 (2013).

2. Janeway, C. A. Jr.  et al.  Immunobiology: The Immune System in Health and Disease. 5th edn (Garland Science, 2001). Available at: https://www.ncbi.nlm.nih.gov/books/NBK27156/

3. Ye, Y., Gaugler, B., Mohty, M. & Malard, F. Plasmacytoid dendritic cell biology and its role in immune-mediated diseases.  Clin. Transl. Immunol.  9, e1139 (2020).

4. Testa, U., Pelosi, E. & Castelli, G. CD123 as a therapeutic target in the treatment of hematological malignancies.  Cancers (Basel)  11, 1358 (2019).

5. Romani, N., Clausen, B. E. & Stoitzner, P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin.  Immunol. Rev.  234, 120–141 (2010).

6. Kim, J. H.  et al.  CD1a on Langerhans cells controls inflammatory skin disease.  Nat. Immunol.  17, 1159–1166 (2016).

7. Valladeau, J., Dezutter-Dambuyant, C. & Saeland, S. Langerin/CD207 sheds light on formation of Birbeck granules and their possible function in Langerhans cells.  Immunol. Res.  28, 93–107 (2003).

8. Felezi, S., Nosrati, A., Eslami Jouybari, M. & Jafarshad, J. Interdigitating dendritic cell tumor of submandibular lymph node: case report and literature review.  Iran. J. Pathol.  16, 237–242 (2021).

9. Chistiakov, D. A., Killingsworth, M. C., Myasoedova, V. A., Orekhov, A. N. & Bobryshev, Y. V. CD68/macrosialin: not just a histochemical marker.  Lab. Invest.  97, 4–13 (2017).

10. Allen, C. D. & Cyster, J. G. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function.  Semin. Immunol.  20, 14–25 (2008).

11. Liu, Y. J.  et al.  Follicular dendritic cells specifically express the long CR2/CD21 isoform.  J. Exp. Med.  185, 165–170 (1997).

12. Engeroff, P. & Vogel, M. The role of CD23 in the regulation of allergic responses.  Allergy  76, 1981–1989 (2021).